PE20140592A1 - Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina - Google Patents
Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidinaInfo
- Publication number
- PE20140592A1 PE20140592A1 PE2013001866A PE2013001866A PE20140592A1 PE 20140592 A1 PE20140592 A1 PE 20140592A1 PE 2013001866 A PE2013001866 A PE 2013001866A PE 2013001866 A PE2013001866 A PE 2013001866A PE 20140592 A1 PE20140592 A1 PE 20140592A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- preparation
- methyl
- refers
- benzoimidazole
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229940095064 tartrate Drugs 0.000 abstract 2
- 102000004187 Histamine H4 receptors Human genes 0.000 abstract 1
- 108090000796 Histamine H4 receptors Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UN HEMITARTRATO CRISTALINO DEL COMPUESTO [5-(4,6-DIMETIL-1H-BENZOIMIDAZOL-2-IL)-4-METIL-PIRIMIDIN-2-IL]-[3-(1-METIL-PIPERIDIN-4-IL)-PROPIL]-AMINA DE FORMULA (I-A) CUYO ESPECTRO DE DIFRACCION DE RAYOS X EN POLVO COMPRENDE LOS SIGUIENTES PICOS EXPRESADOS EN GRADOS 2O: 6.49, 8.58, 9.17, 10.35, 10.75, 16.72, 17.46, 18.89 Y 23.60. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION DEL HEMITARTRATO CRISTALINO QUE COMPRENDE: A) DISOLVER EL COMPUESTO DE FORMULA (I-A) EN UN SOLVENTE ORGANICO; B) CALENTAR LA SOLUCION A UNA PRIMERA TEMPERATURA DE 50 �C; C) ANADIR ACIDO L-TARTARICO PARA FORMAR UNA SOLUCION DE TARTRATO; Y D) CALENTAR LA SOLUCION DE TARTRATO A UNA SEGUNDA TEMPERATURA DE 70 A 75 �C PARA FORMAR UNA MEZCLA CALIENTE. DICHO COMPUESTO ES MODULADOR DEL RECEPTOR H4 DE HISTAMINA SIENDO UTIL EN EL TRATAMIENTO DE LA INFLAMACION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7675908P | 2008-06-30 | 2008-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140592A1 true PE20140592A1 (es) | 2014-05-16 |
Family
ID=41426846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001866A PE20140592A1 (es) | 2008-06-30 | 2009-06-29 | Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20100029942A1 (es) |
| EP (2) | EP2865678A3 (es) |
| JP (2) | JP2011526911A (es) |
| KR (1) | KR20110022721A (es) |
| CN (2) | CN103319459A (es) |
| AR (1) | AR072397A1 (es) |
| AU (1) | AU2009267159B2 (es) |
| BR (1) | BRPI0913989A2 (es) |
| CA (1) | CA2729703A1 (es) |
| CL (1) | CL2010001639A1 (es) |
| CO (1) | CO6341626A2 (es) |
| CR (1) | CR20110057A (es) |
| EA (1) | EA020090B1 (es) |
| EC (1) | ECSP11010744A (es) |
| IL (1) | IL210213A (es) |
| MX (1) | MX2011000081A (es) |
| MY (1) | MY157197A (es) |
| NI (1) | NI201000233A (es) |
| NZ (2) | NZ599747A (es) |
| PE (1) | PE20140592A1 (es) |
| SG (1) | SG192446A1 (es) |
| SV (1) | SV2011003789A (es) |
| TW (2) | TWI485147B (es) |
| UA (1) | UA102855C2 (es) |
| UY (1) | UY31951A (es) |
| WO (1) | WO2010002777A2 (es) |
| ZA (1) | ZA201100760B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5066175B2 (ja) | 2006-03-31 | 2012-11-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリミジンおよびピラジン |
| KR20110022721A (ko) | 2008-06-30 | 2011-03-07 | 얀센 파마슈티카 엔.브이. | 벤조이미다졸-2-일 피리미딘 유도체의 제조 방법 |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| TW201433568A (zh) * | 2008-06-30 | 2014-09-01 | Janssen Pharmaceutica Nv | 製備經取代之嘧啶衍生物的方法 |
| WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| EA201591648A1 (ru) | 2013-03-06 | 2016-02-29 | Янссен Фармацевтика Нв | Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4 |
| WO2017076888A1 (en) * | 2015-11-03 | 2017-05-11 | Janssen Pharmaceutica Nv | 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3005852A (en) | 1959-12-22 | 1961-10-24 | Gen Aniline & Film Corp | Production of sulfoxides and sulfones |
| GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US4337341A (en) * | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
| GB9422391D0 (en) | 1994-11-05 | 1995-01-04 | Solvay Interox Ltd | Oxidation of organosulphur compounds |
| US5945422A (en) * | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| CA2321153A1 (en) | 1998-02-17 | 1999-08-19 | Timothy D. Cushing | Anti-viral pyrimidine derivatives |
| SK16372002A3 (sk) * | 2000-04-24 | 2003-04-01 | Teva Pharmaceutical Industries Ltd. | Zolpidem hemitartrát |
| KR100516535B1 (ko) | 2000-07-21 | 2005-09-22 | 신젠타 파티서페이션즈 아게 | 4,6-디메톡시-2-(메틸설포닐)-1,3-피리미딘의 제조방법 |
| WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| TWI270542B (en) | 2002-02-07 | 2007-01-11 | Sumitomo Chemical Co | Method for preparing sulfone or sulfoxide compound |
| TW200526637A (en) | 2003-09-30 | 2005-08-16 | Janssen Pharmaceutica Nv | Benzoimidazole compounds |
| WO2005081687A2 (en) * | 2003-09-30 | 2005-09-09 | Centocor, Inc. | Human hinge core mimetibodies, compositions, methods and uses |
| BRPI0509164A (pt) | 2004-03-25 | 2007-09-11 | Janssen Pharmaceutica Nv | compostos de imidazol |
| DK1794126T3 (da) * | 2004-09-27 | 2013-06-24 | Acadia Pharm Inc | Krystallinsk form af N-(-4-fluorbenzyl)-N-(1-methylpiperidn-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamid-hemitartrat |
| EP1890703B1 (en) | 2005-06-14 | 2016-05-11 | Taigen Biotechnology | Pyrimidine compounds as chemokine receptors inhibitors |
| JP2009532367A (ja) * | 2006-03-31 | 2009-09-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリジン |
| JP5066175B2 (ja) * | 2006-03-31 | 2012-11-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリミジンおよびピラジン |
| KR20110022721A (ko) | 2008-06-30 | 2011-03-07 | 얀센 파마슈티카 엔.브이. | 벤조이미다졸-2-일 피리미딘 유도체의 제조 방법 |
-
2009
- 2009-06-29 KR KR1020117002003A patent/KR20110022721A/ko not_active Ceased
- 2009-06-29 JP JP2011516759A patent/JP2011526911A/ja active Pending
- 2009-06-29 SG SG2013050083A patent/SG192446A1/en unknown
- 2009-06-29 MY MYPI2010006259A patent/MY157197A/en unknown
- 2009-06-29 NZ NZ599747A patent/NZ599747A/xx not_active IP Right Cessation
- 2009-06-29 CN CN2013102167565A patent/CN103319459A/zh active Pending
- 2009-06-29 US US12/459,224 patent/US20100029942A1/en not_active Abandoned
- 2009-06-29 TW TW103105990A patent/TWI485147B/zh not_active IP Right Cessation
- 2009-06-29 EP EP14193725.0A patent/EP2865678A3/en not_active Withdrawn
- 2009-06-29 NZ NZ590169A patent/NZ590169A/en not_active IP Right Cessation
- 2009-06-29 BR BRPI0913989A patent/BRPI0913989A2/pt not_active Application Discontinuation
- 2009-06-29 AU AU2009267159A patent/AU2009267159B2/en not_active Ceased
- 2009-06-29 AR ARP090102406A patent/AR072397A1/es unknown
- 2009-06-29 CA CA2729703A patent/CA2729703A1/en not_active Abandoned
- 2009-06-29 EA EA201170114A patent/EA020090B1/ru not_active IP Right Cessation
- 2009-06-29 UA UAA201100982A patent/UA102855C2/ru unknown
- 2009-06-29 MX MX2011000081A patent/MX2011000081A/es not_active Application Discontinuation
- 2009-06-29 WO PCT/US2009/049033 patent/WO2010002777A2/en not_active Ceased
- 2009-06-29 TW TW098121914A patent/TW201018668A/zh unknown
- 2009-06-29 CN CN200980134920XA patent/CN102137857A/zh active Pending
- 2009-06-29 PE PE2013001866A patent/PE20140592A1/es not_active Application Discontinuation
- 2009-06-29 EP EP09774228A patent/EP2303869A2/en not_active Withdrawn
- 2009-06-30 UY UY0001031951A patent/UY31951A/es unknown
-
2010
- 2010-12-23 NI NI201000233A patent/NI201000233A/es unknown
- 2010-12-23 IL IL210213A patent/IL210213A/en active IP Right Grant
- 2010-12-30 CL CL2010001639A patent/CL2010001639A1/es unknown
-
2011
- 2011-01-03 SV SV2011003789A patent/SV2011003789A/es unknown
- 2011-01-04 CO CO11000462A patent/CO6341626A2/es not_active Application Discontinuation
- 2011-01-05 EC EC2011010744A patent/ECSP11010744A/es unknown
- 2011-01-28 ZA ZA2011/00760A patent/ZA201100760B/en unknown
- 2011-01-31 CR CR20110057A patent/CR20110057A/es not_active Application Discontinuation
-
2012
- 2012-03-22 US US13/427,798 patent/US8921550B2/en not_active Expired - Fee Related
- 2012-03-22 US US13/427,767 patent/US8835633B2/en not_active Expired - Fee Related
-
2013
- 2013-09-09 JP JP2013186044A patent/JP2014040426A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140592A1 (es) | Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina | |
| JP2013199502A5 (es) | ||
| AR077242A1 (es) | Formas cristalinas del 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}n-(metilsulfonil)acetamida, composiciones farmaceuticas que las contienen, metodo para prepararlas y uso de las mismas en el tratamiento de isquemias, insuficiencia coronaria y asma, entre otras enfermedades. | |
| NZ606001A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| Ge et al. | The synthesis, characterization and optical properties of novel pyrido [1, 2-a] benzimidazole derivatives | |
| CU20150123A7 (es) | DOS FORMAS CRISTALINAS DEL COMPUESTO( 4,6-DIAMINO-2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO?(3,4-b)PIRIDIN-3-IL)PIRIMIDIN-5-IL)CARBAMATO DE METILO | |
| BR112013011593A2 (pt) | cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo | |
| PE20110060A1 (es) | Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida | |
| UA100125C2 (ru) | Способ выделения и очистки монтелукаста | |
| You et al. | Synthesis of 3-(1H-benzo [d] imidazol-1-yl) isoindolin-1-one derivatives promoted by EtOH–AcOH solvent system | |
| CN102050431A (zh) | 一种碲化镉量子点的一步水热合成方法 | |
| AR069305A1 (es) | Nuevos hidratos de difenilazetidinona cristalinos, medicamento que comprenden a estos compuestos y uso de los mismos | |
| Bing et al. | Synthesis of efficient blue and red light emitting phenanthroline derivatives containing both hole and electron transporting properties | |
| PE20131327A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen | |
| Li et al. | Synthesis, structures and photophysical properties of boron–fluorine derivatives based on pyridine/1, 8-naphthyridine | |
| RU2019106531A (ru) | Кристалл соли производного хиназолина | |
| CN102627663A (zh) | 含氟吡啶硼酸的制备方法 | |
| CO6120151A1 (es) | Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina | |
| NZ606180A (en) | (20r,25s)-2-methylene-19,26-dinor-1α, 25-dihydroxyvitamin d3 in crystalline form | |
| Chien et al. | The synthesis and ambipolar charge transport properties of 1, 2, 3, 4-tetrafluoropentacene | |
| CL2012001528A1 (es) | Proceso para preparar la forma cristalina a de ilaprazol a partir de una sal inorganica de ilaprazol y posterior neutralizacion de la sal con un acido en un solvente de reaccion; y proceso para preparar la forma cristalina b de ilaprazol en la forma cristalina a de ilaprazol. | |
| Yang et al. | Synthesis and structure of [C6N4H20] 0.5 [B5O6 (OH) 4]: A new organically templated pentaborate with white-light-emission | |
| CN102633721B (zh) | 一种应用气体重氮甲烷制备吡唑类衍生物的方法 | |
| Khanna et al. | 2, 6-Diarylethynylanthracenes: synthesis, morphology, and electro-optical properties | |
| Mao et al. | Synthesis and Study of Properties for Asymmetric Triphenylamine-Zinc Phthalocyanine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |